Clinical Trial: Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

 Daratumumab is a newer immunotherapy approved by the FDA for relapsed myeloma. Because it has few side effects, many researchers want to see if it can be used in precursor stages of the disease to prevent it from progressing to active myeloma. 

This research study is studying a drug as a possible treatment for Monoclonal Gammopathy of Unknown Significance (MGUS) or Smoldering Multiple Myeloma (SMM). The drug involved in this study is Daratumumab.

The trial is open at the Dana Farber Cancer Institute, run by Dr. Irene Ghobrial, a myeloma specialist with a focus on precursor conditions. It is also open at Beth Israel Deaconess Medical Center in Boston.

To learn more about this trial and sign up to receive notifications, click here: 

Study of the CD38 Antibody Daratumumab Clinical Trial

To find all eligible clinical trials, click here: 

Study of the CD38 Antibody Daratumumab Clinical Trial

About Author

Jenny A

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical trials. Founder of Myeloma Crowd, Myeloma Crowd Radio and the CrowdCare Foundation.

1 Comment

  1. Lawrence Miller on

    This is a great site. wish we had a hospital like this on the West Coast. I have have MGUS that my doctor says his Hi risk because of the three parameters being High. Would love to do something instead of watch and wait.
    Hoping to get into Clinical trail like the Daratummab D38 would be great. I am paying off my home soon and can use the money to Fly out to Boston hopefully participate in the Clinical Trial. My current doctor just runs laboratory test every 3 months for the past couple of years just waiting to get worse ?

Leave A Reply

Please enter the correct captcha code to verify that you are human.